Back to Search
Start Over
Abrocitinib: First Approval.
- Source :
-
Drugs . Dec2021, Vol. 81 Issue 18, p2149-2157. 9p. - Publication Year :
- 2021
-
Abstract
- Abrocitinib (Cibinqo®) is an oral small-molecule inhibitor of Janus kinase 1 (JAK1) being developed by Pfizer for the treatment of moderate-to-severe atopic dermatitis (AD). In September 2021, abrocitinib was approved in the UK and Japan for the treatment of moderate-to-severe AD in adults and adolescents 12 years and older who are candidates for systemic therapy. Abrocitinib has also received a positive CHMP opinion in the EU for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy. Regulatory applications for the drug have also been submitted for review to several other countries, including the USA and Australia. This article summarizes the milestones in the development of abrocitinib leading to this first approval for the treatment of moderate-to-severe AD. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 00126667
- Volume :
- 81
- Issue :
- 18
- Database :
- Academic Search Index
- Journal :
- Drugs
- Publication Type :
- Academic Journal
- Accession number :
- 153978912
- Full Text :
- https://doi.org/10.1007/s40265-021-01638-3